Scarica l'app Stockscreener
16.49
1.14%
-0.19
Dopo l'orario di chiusura:
16.49
Bausch Lomb Corp Borsa (BLCO) Ultime notizie
BLCO SEC FilingsBausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & SuppliesSpecialty Stocks - Yahoo! Finance Canada
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Bausch + Lomb Corporation (BLCO) stock price, news, quote and history - Yahoo Finance Singapore
Should Positive ELIOS Glaucoma Trial Results Require Action From Bausch + Lomb (BLCO) Investors? - simplywall.st
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
Bausch + Lomb to webcast Q1 results and business update April 29 - Stock Titan
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for I - AD HOC NEWS
Tudor Investment Corp ET AL Takes $2.25 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback - Yahoo Finance
Bausch And Lomb (NYSE:BLCO) Shares Draw Eyes Across Nyse Composite Today - kalkinemedia.com
3 Reasons BLCO is Risky and 1 Stock to Buy Instead - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - The Motley Fool
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $19 - 富途牛牛
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System - Intellectia AI
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma - BioSpace
Bausch + Lomb reports positive glaucoma trial results for ELIOS - Investing.com
Glaucoma laser left 82% of patients medication-free in U.S. trial - Stock Titan
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Market Shifts and Deb - AD HOC NEWS
RBC reiterates Bausch & Lomb stock rating on DED rival delay - Investing.com Australia
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
RBC reiterates Bausch & Lomb stock rating on DED rival delay By Investing.com - Investing.com South Africa
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Slowdown and D - AD HOC NEWS
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position - AOL.com
Bausch + Lomb Corporation (NYSE:BLCO) Sees Large Decline in Short Interest - MarketBeat
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Shifts - AD HOC NEWS
Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness - Yahoo Finance
Bausch + Lomb Corporation $BLCO Shares Purchased by Compass Rose Asset Management LP - MarketBeat
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm - GlobeNewswire
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch & Lomb (BLCO) legal chief buys shares and receives 14,600 matching RSUs - Stock Titan
Bausch And Lomb (NYSE:BLCO) Glaucoma Moves Catch Market Eyes Nyse Composite Today - Kalkine Media
Bausch & Lomb (NYSE: BLCO) CFO buys 4,000 shares, gets 4,000 RSUs - Stock Titan
Bausch & Lomb (BLCO) CEO buys 14,700 shares and receives matching RSUs - Stock Titan
Bausch + Lomb Corporation - Baystreet.ca
Inside Bausch + Lomb’s glaucoma webinar on new treatments - Stock Titan
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Latest Revenue And Net Loss Update - Yahoo Finance
Short Covering: Will Bausch Lomb Corporation outperform its industry peersJuly 2025 Levels & Fast Moving Market Watchlists - baoquankhu1.vn
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know - Finviz
Insider Buying: Ross Thomas W. Sr. Acquires Shares in Bausch & L - GuruFocus
Director adds BLCO stake with 4,500-share buy and 4,500 RSUs grant - Stock Titan
Potential Bausch + Lomb Separation Reframes Bausch Health - simplywall.st
Insider Buying: Eduardo Alfonso Acquires Shares of Bausch & Lomb Corp (BLCO) - GuruFocus
[Form 4] Bausch & Lomb Corp Insider Trading Activity - Stock Titan
Bausch & Lomb (NYSE: BLCO) director buys shares, gets RSUs - Stock Titan
BLCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP disposes shares for taxes - Stock Titan
Bausch & Lomb (BLCO) officer has shares withheld for RSU tax - Stock Titan
Tax-withholding share moves by Bausch & Lomb (NYSE: BLCO) executive - Stock Titan
Bausch & Lomb (BLCO) EVP uses share withholding to cover tax on RSU vesting - Stock Titan
Bausch & Lomb (BLCO) EVP uses shares for tax withholding on RSU vesting - Stock Titan
1.21%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):